This is a single-arm, open, multicenter trial of carralizumab in combination with albumin
paclitaxel and apatinib mesylate for the second-line treatment of patients with advanced or
metastatic cholangiocarcinoma. The study enlists patients with histopathologically or
cytologically confirmed unresectable, recurrent, or metastatic cholangiocarcinoma (including
intrahepatic, extrahepatic, and distal cholangiocarcinoma). Previously, she had received
systematic internal medicine anti-tumor therapy with gemcitabine regimen as standard, which
met the inclusion criteria of this study. She was given oral therapy with albumin binding
paclitaxel combined with carrilizumab and apatinib mesylate. Treatment continued or was
evaluated every 2 cycles until disease progression or toxic side effects of patient
intolerance to the treatment regimen. To evaluate progression-free survival (PFS) in
second-line therapy with carrilizumab in combination with albumin paclitaxel and apatinib
mesylate in patients with advanced or metastatic cholangiocarcinoma.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University